Gene · 3598
Papers2,877
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
921 to 940 of 2,877
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Antimicrobial protein REG3A and signaling networks are predictive of stroke outcomes. | J Neurochem | 2022 | 34558059 | PubTator, text mining | PubMed |
| Nanomedicine and graphene-based materials: advanced technologies for potential treatments of diseases in the developing nervous system. | Pediatr Res | 2022 | 34480086 | PubTator, text mining | PubMed |
| Patients with systemic sclerosis show phenotypic and functional defects in neutrophils. | Allergy | 2022 | 34467524 | PubTator, text mining | PubMed |
| Butyrate and propionate restore interleukin 13-compromised esophageal epithelial barrier function. | Allergy | 2022 | 34458999 | PubTator, text mining | PubMed |
| Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. | Nat Rev Drug Discov | 2022 | 34417579 | PubTator, text mining | PubMed |
| Genetic association of primary nonresponse to anti-TNFα therapy in patients with inflammatory bowel disease. | Pharmacogenet Genomics | 2022 | 34380996 | PubTator, text mining | PubMed |
Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology. | Acta Otorhinolaryngol Ital | 2022 | 34297014 | PubTator, text mining | PubMed |
| The antigen-binding moiety in the driver's seat of CARs. | Med Res Rev | 2022 | 34028069 | PubTator, text mining | PubMed |
| Engineered cells as glioblastoma therapeutics. | Cancer Gene Ther | 2022 | 33753869 | PubTator, text mining | PubMed |
If Artificial In Vitro Microenvironment Can Influence Tumor Drug Resistance Network via Modulation of lncRNA Expression?-Comparative Analysis of Glioblastoma-Derived Cell Culture Models and Initial Tumors In Vivo. | Cell Mol Neurobiol | 2022 | 33245508 | PubTator, text mining | PubMed |
| A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs. | Front Bioinform | 2021 | 36303796 | PubTator, text mining | PubMed |
| Phase I clinical trials in adoptive T-cell therapies. | J R Stat Soc Ser C Appl Stat | 2021 | 36017232 | PubTator, text mining | PubMed |
| Pharmacological, Technological, and Digital Innovative Aspects in Rhinology. | Front Allergy | 2021 | 35387050 | PubTator, text mining | PubMed |
| A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine. | Front Immunol | 2021 | 35126356 | PubTator, text mining | PubMed |
| Biologics in Asthma: A Molecular Perspective to Precision Medicine. | Front Pharmacol | 2021 | 35126131 | PubTator, text mining | PubMed |
| Immunotherapy and radiation for high-grade glioma: a narrative review. | Transl Cancer Res | 2021 | 35116570 | PubTator, text mining | PubMed |
| Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma. | Front Oncol | 2021 | 35096619 | PubTator, text mining | PubMed |
| Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets. | Front Physiol | 2021 | 35095572 | PubTator, text mining | PubMed |
| Transcriptomic and Lipidomic Profiles in Nasal Polyps of Glucocorticoid Responders and Non-Responders: Before and After Treatment. | Front Pharmacol | 2021 | 35095530 | PubTator, text mining | PubMed |
| Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting? | Front Med Technol | 2021 | 35047971 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3598/papers?page=47